Announcements Trials
Browse Landscape

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Gastrointestinal 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Papillomavirus Infections 1

Interventions

pembrolizumab 66Cisplatin 55Radiotherapy, Intensity-Modulated 28Carboplatin 27Nivolumab 26Paclitaxel 21Magnetic Resonance Spectroscopy 21Radiotherapy 20Cetuximab 16Specimen Handling 15Docetaxel 15Radiation 14Gemcitabine 13Fluorouracil 12Biopsy 12durvalumab 11Platinum 11Taxes 10Drug Therapy 101,2-diaminocyclohexaneplatinum II citrate 10Surveys and Questionnaires 9Capecitabine 9trametinib 8tislelizumab 6lenvatinib 6dabrafenib 6cemiplimab 6atezolizumab 6Radiosurgery 6Ipilimumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Mass Screening × Head & Neck × Clear all
NCT04965792 2025-06-17

Post-treatment Surveillance in HPV+ Oropharyngeal SCC

Dana-Farber Cancer Institute

Active not recruiting
150 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡